CZ20032767A3 - Sloučeniny a léčiva pro použití pro inhibici tvorby adhezí - Google Patents
Sloučeniny a léčiva pro použití pro inhibici tvorby adhezí Download PDFInfo
- Publication number
- CZ20032767A3 CZ20032767A3 CZ20032767A CZ20032767A CZ20032767A3 CZ 20032767 A3 CZ20032767 A3 CZ 20032767A3 CZ 20032767 A CZ20032767 A CZ 20032767A CZ 20032767 A CZ20032767 A CZ 20032767A CZ 20032767 A3 CZ20032767 A3 CZ 20032767A3
- Authority
- CZ
- Czechia
- Prior art keywords
- carbon atoms
- alkyl
- group
- moiety
- het
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 16
- 150000001875 compounds Chemical class 0.000 title claims description 27
- 239000003814 drug Substances 0.000 title claims description 8
- 230000005764 inhibitory process Effects 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 claims description 96
- 125000000217 alkyl group Chemical group 0.000 claims description 40
- 229910052799 carbon Inorganic materials 0.000 claims description 22
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 17
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 125000004429 atom Chemical group 0.000 claims description 13
- 125000005843 halogen group Chemical group 0.000 claims description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- -1 methylenedioxy Chemical group 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 3
- PVDGZHKJXXVONO-INIZCTEOSA-N 2-[(4s)-3-oxo-8-[3-(pyridin-2-ylamino)propoxy]-2-(2,2,2-trifluoroethyl)-4,5-dihydro-1h-2-benzazepin-4-yl]acetic acid Chemical compound C([C@H](C(N(CC(F)(F)F)CC1=C2)=O)CC(=O)O)C1=CC=C2OCCCNC1=CC=CC=N1 PVDGZHKJXXVONO-INIZCTEOSA-N 0.000 claims description 2
- KSSPHFGIOASRDE-HNNXBMFYSA-N 2-[(4s)-8-[2-[6-(methylamino)pyridin-2-yl]ethoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-4,5-dihydro-1h-2-benzazepin-4-yl]acetic acid Chemical compound CNC1=CC=CC(CCOC=2C=C3CN(CC(F)(F)F)C(=O)[C@H](CC(O)=O)CC3=CC=2)=N1 KSSPHFGIOASRDE-HNNXBMFYSA-N 0.000 claims description 2
- BGYNBQAHKJEEHJ-QFIPXVFZSA-N 2-[(6s)-2-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-6,11-dihydro-5h-dibenzo[3,2-[7]annulen-6-yl]acetic acid Chemical compound C1=C2CC3=CC=CC=C3[C@H](CC(=O)O)CC2=CC=C1OCCC1=CC=C(CCCN2)C2=N1 BGYNBQAHKJEEHJ-QFIPXVFZSA-N 0.000 claims description 2
- RGICCULPCWNRAB-UHFFFAOYSA-N 2-[2-(2-hexoxyethoxy)ethoxy]ethanol Chemical compound CCCCCCOCCOCCOCCO RGICCULPCWNRAB-UHFFFAOYSA-N 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 239000013256 coordination polymer Substances 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 102100022337 Integrin alpha-V Human genes 0.000 abstract description 14
- 108010048673 Vitronectin Receptors Proteins 0.000 abstract description 14
- 239000002464 receptor antagonist Substances 0.000 abstract description 12
- 229940044551 receptor antagonist Drugs 0.000 abstract description 12
- 241001465754 Metazoa Species 0.000 description 19
- 210000000936 intestine Anatomy 0.000 description 19
- 238000001356 surgical procedure Methods 0.000 description 19
- 241000283973 Oryctolagus cuniculus Species 0.000 description 14
- 229940125904 compound 1 Drugs 0.000 description 13
- 238000000034 method Methods 0.000 description 11
- 238000011887 Necropsy Methods 0.000 description 9
- 239000000902 placebo Substances 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- 238000009472 formulation Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 235000002639 sodium chloride Nutrition 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 206010060932 Postoperative adhesion Diseases 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 206010061401 Uterine injury Diseases 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 1
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000032984 Intraoperative Complications Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000034827 Neointima Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010034238 Pelvic adhesions Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 102000019997 adhesion receptor Human genes 0.000 description 1
- 108010013985 adhesion receptor Proteins 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 1
- 229960004563 eprosartan Drugs 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 210000005119 human aortic smooth muscle cell Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002632 myometrial effect Effects 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28269301P | 2001-04-10 | 2001-04-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CZ20032767A3 true CZ20032767A3 (cs) | 2004-12-15 |
Family
ID=23082703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ20032767A CZ20032767A3 (cs) | 2001-04-10 | 2002-04-10 | Sloučeniny a léčiva pro použití pro inhibici tvorby adhezí |
Country Status (26)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR052823A1 (es) * | 2004-12-21 | 2007-04-04 | Smithkline Beecham Corp | Uso de un antagonista del receptor de vitronectina para l a preparacion de una formulacion farmaceutica util para inhibir el exceso de formacion de cicatrices en la piel de a un mamifero y dicha formulacion |
| RU2744540C1 (ru) * | 2020-02-18 | 2021-03-11 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ профилактики спаечного процесса при операциях на брюшной полости в условиях паренхиматозного кровотечения в эксперименте |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA60311C2 (uk) * | 1996-10-02 | 2003-10-15 | Смітклайн Бічам Корпорейшн | Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція |
-
2002
- 2002-04-10 WO PCT/US2002/011285 patent/WO2002083125A1/en not_active Ceased
- 2002-04-10 HU HU0303725A patent/HUP0303725A3/hu unknown
- 2002-04-10 CA CA002443734A patent/CA2443734A1/en not_active Abandoned
- 2002-04-10 KR KR10-2003-7013214A patent/KR20030087069A/ko not_active Abandoned
- 2002-04-10 MX MXPA03009344A patent/MXPA03009344A/es active IP Right Grant
- 2002-04-10 CZ CZ20032767A patent/CZ20032767A3/cs unknown
- 2002-04-10 CN CNB028097874A patent/CN1248692C/zh not_active Expired - Fee Related
- 2002-04-10 IL IL15827202A patent/IL158272A0/xx unknown
- 2002-04-10 EA EA200301109A patent/EA006202B1/ru not_active IP Right Cessation
- 2002-04-10 NZ NZ528577A patent/NZ528577A/en unknown
- 2002-04-10 PL PL02364526A patent/PL364526A1/xx not_active Application Discontinuation
- 2002-04-10 BR BR0208789-8A patent/BR0208789A/pt not_active IP Right Cessation
- 2002-04-10 DE DE60230404T patent/DE60230404D1/de not_active Expired - Lifetime
- 2002-04-10 AT AT02733968T patent/ATE417612T1/de not_active IP Right Cessation
- 2002-04-10 AU AU2002305164A patent/AU2002305164B2/en not_active Ceased
- 2002-04-10 ES ES02733968T patent/ES2319877T3/es not_active Expired - Lifetime
- 2002-04-10 JP JP2002580929A patent/JP4394882B2/ja not_active Expired - Fee Related
- 2002-04-10 OA OA1200300271A patent/OA12505A/en unknown
- 2002-04-10 AP APAP/P/2003/002894A patent/AP2003002894A0/en unknown
- 2002-04-10 EP EP02733968A patent/EP1385504B1/en not_active Expired - Lifetime
- 2002-10-04 UA UA2003109182A patent/UA75395C2/uk unknown
-
2003
- 2003-09-30 ZA ZA200307621A patent/ZA200307621B/en unknown
- 2003-10-01 BG BG108217A patent/BG108217A/bg unknown
- 2003-10-06 MA MA27339A patent/MA26159A1/fr unknown
- 2003-10-08 NO NO20034513A patent/NO20034513L/no not_active Application Discontinuation
- 2003-10-09 EC EC2003004799A patent/ECSP034799A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UA75395C2 (en) | 2006-04-17 |
| KR20030087069A (ko) | 2003-11-12 |
| EP1385504B1 (en) | 2008-12-17 |
| EA006202B1 (ru) | 2005-10-27 |
| BR0208789A (pt) | 2004-03-09 |
| ZA200307621B (en) | 2004-04-21 |
| CN1248692C (zh) | 2006-04-05 |
| HUP0303725A3 (en) | 2009-08-28 |
| ES2319877T3 (es) | 2009-05-14 |
| IL158272A0 (en) | 2004-05-12 |
| CN1509170A (zh) | 2004-06-30 |
| NZ528577A (en) | 2005-01-28 |
| MXPA03009344A (es) | 2004-02-12 |
| JP4394882B2 (ja) | 2010-01-06 |
| AP2003002894A0 (en) | 2003-12-31 |
| AU2002305164B2 (en) | 2005-07-28 |
| DE60230404D1 (cg-RX-API-DMAC7.html) | 2009-01-29 |
| HUP0303725A2 (hu) | 2004-03-01 |
| EA200301109A1 (ru) | 2004-02-26 |
| OA12505A (en) | 2006-05-29 |
| BG108217A (bg) | 2004-12-30 |
| ECSP034799A (es) | 2004-01-28 |
| EP1385504A4 (en) | 2007-03-14 |
| CA2443734A1 (en) | 2002-10-24 |
| PL364526A1 (en) | 2004-12-13 |
| EP1385504A1 (en) | 2004-02-04 |
| NO20034513L (no) | 2003-12-04 |
| ATE417612T1 (de) | 2009-01-15 |
| MA26159A1 (fr) | 2004-07-01 |
| NO20034513D0 (no) | 2003-10-08 |
| WO2002083125A1 (en) | 2002-10-24 |
| JP2004525959A (ja) | 2004-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101717410A (zh) | 含磷化合物及其应用 | |
| JP2003501151A (ja) | 動脈再狭窄治療用装置および化合物 | |
| US20080058303A1 (en) | Use of melagatran | |
| CA2737163C (en) | Methods of treatment of hyperuricemia and associated disease states | |
| CN100377742C (zh) | 包含低分子量凝血酶抑制剂及其药物前体的药用制剂 | |
| CZ20032767A3 (cs) | Sloučeniny a léčiva pro použití pro inhibici tvorby adhezí | |
| KR20050100676A (ko) | 아세틸살리실산 및 안지오텐신 ⅱ 길항제와 배합된디피리다몰의 뇌졸중 예방을 위한 용도 | |
| CN102046163A (zh) | 使用乌地那非(udenafil)与阿呋唑嗪(alfuzosin)或奥昔布宁(oxybutynin)组合治疗膀胱过度活动症 | |
| EA007952B1 (ru) | Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной артериальной гипертензии | |
| JP2023527358A (ja) | 肺線維症を処置する方法 | |
| AU2002305164A1 (en) | Method of inhibiting adhesion formation | |
| JP2009533413A (ja) | 鎮痛剤およびビタミンを含む医薬組成物 | |
| US20040142918A1 (en) | Method of inhibiting adhesion formation | |
| JP2006510613A (ja) | ３，７−ジアザビシクロ［３．３．１］ノナン化合物を含有する液体医薬組成物および抗不整脈事象に関する治療法 | |
| JP4955392B2 (ja) | 血管内膜過増殖疾患の予防または治療剤 | |
| JPH06157311A (ja) | 血管病変治療剤 |